Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;15(5):e70567.
doi: 10.1002/brb3.70567.

Cenobamate in Real-Word Scenario: Results on Efficacy, Side Effects, and Retention Rate in a Single Center Retrospective Study

Mostafa Badr  1 , Christoph Helmstaedter  1 , Susanna Moskau-Hartmann  1 , Jan Pukropski  1 , Juri-Alexander Witt  1 , Theodor Rüber  1 , Karmele Olaciregui Dague  1 , Tobias Baumgartner  1 , Michael Rademacher  1 , Rainer Surges  1 , Randi von Wrede  1
Affiliations

Cenobamate in Real-Word Scenario: Results on Efficacy, Side Effects, and Retention Rate in a Single Center Retrospective Study

Mostafa Badr et al. Brain Behav. 2025 May.

Abstract

Background: Pharmacoresistance imposes a high burden on people with epilepsy (PWE). Recently authorized cenobamate (CNB) offers new hope with high efficacy reported in phase III and early real-world studies. Here, we present data from a reasonably sized monocentric cohort, complementing the knowledge derived from clinical practice.

Methods: We retrospectively analyzed medical records of all PWE treated with CNB from market entry to July 31, 2023.

Results: After an average of 1.1 years, follow-up data were available for 262 out of 280 PWE, who received at least one dose of CNB. The average CNB dose was 183 ± 98 mg/d, with a mean number of anti-seizure medications (ASM) of 2.9 ± 1 per patient. A total of 36% of the patients showed ≥ 50% reduction in seizure frequency (10.7% were seizure-free), whilst 12.3% reported increased seizure frequency. Seizure freedom was associated with concomitant perampanel or GABA receptor modulators. No predictors of treatment response were found. Side effects were reported by 38%, alertness issues being most prevalent (19%). The retention rate amounted to 72% and was associated with response status, dose of CNB, side effects, and age at CNB introduction. Among those who discontinued CNB, 55% experienced side effects and 89% showed no meaningful seizure reduction. Regarding co-medication, the withdrawal of lamotrigine, brivaracetam, clobazam, or lacosamide was associated with higher rates of non-response.

Conclusions: In this large cohort of 262 PWE, CNB proved very efficient with a high retention rate over one year. Co-medication with perampanel or GABA receptor modulators was linked to seizure-freedom. The overall positive impression of CNB is further supported.

Keywords: cenobamate; efficacy; real‐world data; retention rate; side effects.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Efficacy and retention of CNB.
FIGURE 2
FIGURE 2
Side effects of CNB.
FIGURE 3
FIGURE 3
Percentage of withdrawal of concomitant ASMs and its effect.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Beltrán‐Corbellini, Á. , Romeral‐Jiménez M., Mayo P., et al. 2023. “Cenobamate in Patients With Highly Refractory Focal Epilepsy: A Retrospective Real‐World Study.” Seizure 111: 71–77. 10.1016/j.seizure.2023.07.026. - DOI - PubMed
    1. Bialer, M. , Johannessen S. I., Levy R. H., Perucca E., Tomson T., and White H. S. 2013. “Progress Report on New Antiepileptic Drugs: A Summary of the Eleventh Eilat Conference (EILAT XI).” Epilepsy Research 103, no. 1: 2–30. 10.1016/j.eplepsyres.2012.10.001. - DOI - PubMed
    1. Brigo, F. , and Lattanzi S. 2024. “Cenobamate Add‐on Therapy for Drug‐Resistant Focal Epilepsy.” Cochrane Database of Systematic Reviews 8, no. 8: CD014941. 10.1002/14651858.cd014941.pub2. - DOI - PMC - PubMed
    1. Carreño, M. , Gil‐Nagel A., Serratosa J. M., Toledo M., Rodriguez‐Uranga J. J., and Villanueva V. 2024. “Spanish Consensus on the Management of Concomitant Antiseizure Medications When Using Cenobamate in Adults With Drug‐resistant Focal Seizures.” Epilepsia Open 9, no. 3: 1051–1058. 10.1002/epi4.12936. - DOI - PMC - PubMed
    1. Chen, Z. , Brodie M. J., Liew D., and Kwan P. 2018. “Treatment Outcomes in Patients with Newly Diagnosed Epilepsy Treated with Established and New Antiepileptic Drugs: a 30‐Year Longitudinal Cohort Study.” JAMA Neurology 75, no. 3: 279–286. 10.1001/jamaneurol.2017.3949. - DOI - PMC - PubMed

MeSH terms